All Industry News articles
-
News CRISPR-based therapeutics hold potential to combat AMR and cure chronic viral infections, says GlobalData
CRISPR-based therapeutics show potential to combat antimicrobial resistance (AMR) and deliver functional cures for chronic viral infections, says GlobalData, a leading data and analytics company.
-
NewsAI poised to revolutionize Lyme disease testing and treatment
Researchers unveiled a blood test developed with the help of artificial intelligence (AI) that identifies Lyme disease sooner and more accurately than the current standard — and that could translate to vastly improved patient outcomes.
-
NewsFlightpath Biosciences licenses microbiome-sparing antibiotic developed at Illinois
Flightpath Biosciences, Inc., has licensed a class of antibiotics developed at the University of Illinois Urbana-Champaign. The original antibiotic agent, lolamicin, effectively treated bacterial infections in animal models of disease without wiping out beneficial gut microbes.
-
News BugBiome to test lead bioinsecticide in sugar beet field trials with partner Niab
BugBiome, an agritech innovator developing new bioinsecticides from crop-associated microbes, is field testing its lead product against aphids via a new Innovate UK grant with partner Niab, an experienced crop trial specialist.
-
NewsAFYREN begins new phase of industrial strategy as first plant AFYREN NEOXY achieves continuous production
Greentech company AFYREN offering industrial customers bio-based, low-carbon products through fermentation technology based on a circular model, announced its first plant has achieved continuous production, enabling acceleration of commercialization.
-
NewsSmart plastics are key to curbing healthcare infection rates, says Symphony Environmental
A leading plastics innovator urges hospitals and care-homes to adopt antimicrobial smart plastic solutions to address infection rates.
-
NewsTransatlantic collaboration to develop therapeutic for Crimean-Congo Hemorrhagic Fever
A new transatlantic collaboration will look to develop an affordable and accessible monoclonal antibody therapeutic for Crimean-Congo Hemorrhagic Fever Virus (CCHFV), which could treat and protect thousands of people globally.
-
NewsAFYREN strengthens its Executive Committee with appointment of Laurent Pou as Industrial Director
AFYREN, a greentech company offering manufacturers biobased, low-carbon ingredients through a unique fermentation technology based on a circular model, has announced the appointment of Laurent Pou as Industrial Director.
-
NewsPhage therapy at a crossroads: global experts gather for ground-breaking 2025 Congress
Global multidisciplinary experts and innovators convene for the 8th World Congress on Targeting Phage Therapy 2025 on June 10-11. This leading event is dedicated to the advancement of bacteriophage science and applications in multiple bioscience areas.
-
NewsUpdated guidelines for pediatric Mycoplasma pneumoniae infection
In light of the rise in antibiotic resistance, new guidelines are released with detailed recommendations of diagnosis and treatment strategies for pediatric Mycoplasma pneumoniae pneumonia (MPP), along with the means to manage severe complications.
-
NewsTecovirimat is safe but ineffective as treatment for clade II mpox
The antiviral drug tecovrimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial.
-
NewsDrug may prevent COVID-19 in exposed people within households, major trial finds
An international clinical trial of the oral antiviral drug, ensitrelvir, which has been proved to prevent COVID-19 cases, was conducted and found to be very effective. The drug will be awaiting for approval before becoming widely available.
-
NewsFA Bio licenses two microbes to IFF’s Crop Biologicals division to advance microbial solutions for crop health
FA Bio, a leader in the discovery of sustainable agricultural products, has extended a license agreement on two microbials to IFF’s Crop Biologicals business.
-
NewsScottish biotech company Lentitek secures £1m funding to advance next generation cancer treatments
Biotech company Lentitek Ltd has secured £700,000 in private funding from Equity Gap, bringing its total investment to £1 million in the last six months. It develops manufacturing technologies for lentiviral vectors, used with CAR-T cell and gene therapies.
-
NewsCentauri Therapeutics selects first clinical candidate for immunotherapeutic treatment of Gram-negative bacterial infections
Centauri Therapeutics Limited has announced the selection of its first clinical candidate in the ABX-01 programme. The compound is designed to target serious Gram-negative bacterial infections in the lung.
-
NewsNewly launched Enodia Therapeutics is a biotech company with a new approach for targeted protein degradation
Argobio and the Institut Pasteur have announced the launch of Enodia Therapeutics, a groundbreaking French biotech company dedicated to block and degrade disease-causing proteins for treating cancer, inflammatory diseases and viral infections.
-
NewsStudy reveals how bacteria in microbiome medicine trigger tumor-killing cells
Microbiotica has presented new data on the mechanism of action of MB097, a clinical-stage drug candidate being developed as a co-therapy in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma.
-
NewsBeacon Technology Solutions, Illinois Tech awarded grant to advance far-UVC disinfection research
Beacon Technology Solutions, with collaborators at Illinois Institute of Technology, has been awarded a grant to support a novel study on how Far-UVC technology can help mitigate the spread of infectious diseases in public spaces.
-
NewsScottish bio-tech company secures £3.4m investment
Scottish biotech engineering company uFraction8 has secured £3.4m in new investment following the completion of a funding round led by Foresight Group.
-
NewsLancaster University spinout secures funding to advance healthcare diagnostics
Lancaster University spin out CCI Photonics has secured significant funding to develop its diagnostic technology, which aims to improve healthcare outcomes by using AI to detect infectious diseases and determine patients’ antibiotic susceptibilities in under 15 minutes.